GlobeImmune (GlobeImmune) GF Value Rank : 0 (As of May. 21, 2024)

View and export this data going back to 2014. Start your Free Trial

What is GlobeImmune GF Value Rank?

GlobeImmune has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

GlobeImmune GF Value Rank Related Terms

Thank you for viewing the detailed overview of GlobeImmune's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

GlobeImmune (GlobeImmune) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeImmune Inc (OTCPK:GBIM) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1450 Infinite Drive, Louisville, CO, USA, 80027

Website

http://www.globeimmune.com

GlobeImmune Inc is a US-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.

Executives

Augustine Lawlor	director	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Daniel J Mitchell	director
S. Edward Torres	director	C/O LILLY VENTURES FUND I LLC, 115 W. WASHINGTON ST, STE 1680 SOUTH, INDIANAPOLIS IN 46204
Healthcare Ventures Vii Lp	other: Former 10% Owner	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
John W Littlechild	other: Former 10% Owner	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
James H Cavanaugh	other: Former 10% Owner	265 HOTHORPE LANE, VILLANOVA PA 19085
Harold R Werner	other: Former 10% Owner	C/O HEALTHCARE VENTURES LLC, 44 NASSAU STREET, PRINCETON NJ 08542
Christopher Mirabelli	other: Former 10% Owner	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Healthcare Partners Vii, L.p.	other: Former 10% Owner	44 NASSAU STREET, PRINCETON NJ 08542
J William Freytag	director
Rodell Timothy C Jr	director, officer: CEO & Pres	201 MIDLAND AVE, ASPEN CO 81611
Celgene Corp /de/	10 percent owner	86 MORRIS AVENUE, SUMMIT NJ 07901
Morgenthaler Partners Vii Lp	10 percent owner	50 PUBLIC SQUARE, SUITE 2700, CLEVELAND OH 44113

GlobeImmune (GlobeImmune) Headlines

No Headlines